Mardi Gomberg-Maitland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mardi Gomberg-Maitland has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Raymond L. Benza
4 shared publicationsRicha Agarwal
New York Presbyterian Hospital, Section of Cardiology, Columbia University, New York, NY, USA
4 shared publications- Thenappan Thenappan
University of Minnesota
4 shared publications Vallerie V. McLaughlin
3 shared publications- Victor Mor-Avi
University of Chicago Medical Center, Chicago, Illinois, USA
3 shared publications Adaani Frost
2 shared publications
Latest Publications
- 2 April 2015
- Published by Springer Nature in Current Hypertension Reports
- Vol. 17 (5) , 1-10
Management of Pulmonary Hypertension and Right Heart Failure in the Intensive Care Unit
Management of acute right ventricular failure, both with and without coexisting pulmonary hypertension, is a common challenge encountered in the intensive care setting. Both right ventricular dysfunction and pulmonary hypertension portend a poor prognosis, regardless of the underlying cause and are associated with significant morbidity and mortality. The right ventricle is embryologically distinct from the left ventricle and has unique morphologic and functional properties. Management of right ventricular failure and pulmonary hypertension in the intensive care setting requires tailored hemodynamic management, pharmacotherapy, and often mechanical circulatory support. Unfortunately, our understanding of the management of right ventricular failure lags behind that of the left ventricle. In this review, we will explore the underlying pathophysiology of the failing right ventricle and pulmonary vasculature in patients with and without pulmonary hypertension and discuss management strategies based on evidence-based studies as well as our current understanding of the underlying physiology.
- 2 April 2015
- Published by Springer Nature in Current Hypertension Reports
- Vol. 17 (5) , 1-10
Management of Pulmonary Hypertension and Right Heart Failure in the Intensive Care Unit
Management of acute right ventricular failure, both with and without coexisting pulmonary hypertension, is a common challenge encountered in the intensive care setting. Both right ventricular dysfunction and pulmonary hypertension portend a poor prognosis, regardless of the underlying cause and are associated with significant morbidity and mortality. The right ventricle is embryologically distinct from the left ventricle and has unique morphologic and functional properties. Management of right ventricular failure and pulmonary hypertension in the intensive care setting requires tailored hemodynamic management, pharmacotherapy, and often mechanical circulatory support. Unfortunately, our understanding of the management of right ventricular failure lags behind that of the left ventricle. In this review, we will explore the underlying pathophysiology of the failing right ventricle and pulmonary vasculature in patients with and without pulmonary hypertension and discuss management strategies based on evidence-based studies as well as our current understanding of the underlying physiology.
- 11 October 2014
- Published by Springer Nature in Current Hypertension Reports
- Vol. 16 (12)
New Pharmacotherapies for Pulmonary Hypertension: Where Do They Fit in?
Pulmonary arterial hypertension (PAH) is a rare, progressively worsening disease characterized by dysfunction among endothelial and smooth muscle cells within the pulmonary vasculature with a resultant increase in pulmonary vascular resistance, right ventricular maladaptation and failure, and ultimately early death. The three major therapeutic classes of medications available to treat PAH act as either prostacyclin analogs or endothelin receptor antagonists (ERAs) or by increasing local nitric oxide (NO) levels by means of phosphodiesterase type 5 inhibitors. Several recent trials have investigated the use of oral prostanoid therapy, next-generation ERAs, and soluble guanylate cyclase stimulators (to increase NO levels) as well as novel formulations of pre-existing therapies. The goal of this manuscript is to briefly review established therapies and then discuss recent developments and practical considerations in each of the major drug classes.
- 11 October 2014
- Published by Springer Nature in Current Hypertension Reports
- Vol. 16 (12)
New Pharmacotherapies for Pulmonary Hypertension: Where Do They Fit in?
Pulmonary arterial hypertension (PAH) is a rare, progressively worsening disease characterized by dysfunction among endothelial and smooth muscle cells within the pulmonary vasculature with a resultant increase in pulmonary vascular resistance, right ventricular maladaptation and failure, and ultimately early death. The three major therapeutic classes of medications available to treat PAH act as either prostacyclin analogs or endothelin receptor antagonists (ERAs) or by increasing local nitric oxide (NO) levels by means of phosphodiesterase type 5 inhibitors. Several recent trials have investigated the use of oral prostanoid therapy, next-generation ERAs, and soluble guanylate cyclase stimulators (to increase NO levels) as well as novel formulations of pre-existing therapies. The goal of this manuscript is to briefly review established therapies and then discuss recent developments and practical considerations in each of the major drug classes.
- 1 December 2013
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 32 (12) , 1179-1186
Survival in pulmonary arterial hypertension patients awaiting lung transplantation
- 1 December 2013
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 32 (12) , 1179-1186
Survival in pulmonary arterial hypertension patients awaiting lung transplantation
- 27 May 2013
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 173 (10) , 887-893
Referral of Patients With Pulmonary Hypertension Diagnoses to Tertiary Pulmonary Hypertension Centers
Research from JAMA Internal Medicine — Referral of Patients With Pulmonary Hypertension Diagnoses to Tertiary Pulmonary Hypertension Centers — The Multicenter RePHerral Study
- 27 May 2013
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 173 (10) , 887-893
Referral of Patients With Pulmonary Hypertension Diagnoses to Tertiary Pulmonary Hypertension Centers
Research from JAMA Internal Medicine — Referral of Patients With Pulmonary Hypertension Diagnoses to Tertiary Pulmonary Hypertension Centers — The Multicenter RePHerral Study
- 1 July 2012
- Published by Elsevier in Heart Failure Clinics
- Vol. 8 (3) , 373-383
Prognostication in Pulmonary Arterial Hypertension
- 1 July 2012
- Published by Elsevier in Heart Failure Clinics
- Vol. 8 (3) , 373-383
Prognostication in Pulmonary Arterial Hypertension
- 1 May 2012
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 31 (5) , 467-477
Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction
- 1 May 2012
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 31 (5) , 467-477
Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction
- Open Access
- 1 January 2012
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 14 (1) , 11
Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension
- 1 January 2012
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 14 (1) , 11
Open AccessLate gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension